{{ currentBoardShortName }}
  • Markets
  • Indices
  • FX
  • Energy
  • Metals
Markets
As of: {{timeStamp.date}}
{{timeStamp.time}}

Markets

{{ currentBoardShortName }}
  • Markets
  • Indices
  • FX
  • Energy
  • Metals
{{data.symbol | reutersRICLabelFormat:group.RICS}}
 
{{data.netChng | number: 4 }}
{{data.netChng | number: 2 }}
{{data | displayCurrencySymbol}} {{data.price | number: 4 }}
{{data.price | number: 2 }}
{{data.symbol | reutersRICLabelFormat:group.RICS}}
 
{{data.netChng | number: 4 }}
{{data.netChng | number: 2 }}
{{data | displayCurrencySymbol}} {{data.price | number: 4 }}
{{data.price | number: 2 }}
  • BREAKING NEWS

    PRIVATEBANCORP POSTPONES SPECIAL MEETING TO VOTE ON CIBC TAKEOVER
  • BREAKING NEWS

    DOLLARAMA Q3 SAME-STORE SALES ROSE 5.1%
  • BREAKING NEWS

    DOLLARAMA Q3 REVENUE MATCHES ANALYST EXPECTATIONS
  • BREAKING NEWS

    DOLLARAMA Q3 EPS $0.92 VS EST $0.87

Latest Videos

{{ currentStream.Name }}

Related Video

Continuous Play:
ON OFF

The information you requested is not available at this time, please check back again soon.

Nov 30

Valeant plunges after talks to sell Salix unit reportedly break down

Pharmaceuticals

Security Not Found

The stock symbol {{StockChart.Ric}} does not exist

See Full Stock Page »

Valeant Pharmaceuticals International (VRX.TO) shares tumbled Wednesday after The Wall Street Journal reported talks to sell the drugmaker’s Salix unit to Takeda Pharmaceutical Co. for US$10 billion have broken down.  

Valeant’s stock was down seven per cent on the NYSE as of 12:45 p.m. ET.

Valeant confirmed it was in talks to sell Salix, its stomach-drug unit, to Japanese pharma company Takeda earlier this month.

Takeda tried earlier in the year to buy Salix as part of a joint bid with private equity firm TPG but the approach, which came a few weeks before Joseph Papa took over as Valeant’s chief executive, was rejected by the board, according to a Reuters report.

Valeant acquired Salix for US$14.5 billion in 2015.